Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Medronic Acid→

Medronic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1984-15-2
Molecular formula
CH6O6P2
Molecular weight
176 g/mol
Drug class
Bisphosphonate liganddiagnostic radiopharmaceutical precursor for technetium-99m skeletal imaging
Mechanism of action
Medronic acid (methylene diphosphonate, MDP) chelates technetium-99m after reconstitution of a radiopharmaceutical kit. The labelled complex has affinity for hydroxyapatite in bone and accumulates in proportion to regional blood flow and osteoblastic activity, allowing skeletal scintigraphy.
Indications / reported uses
  • Used as the active ligand in technetium Tc-99m medronate (Tc-99m MDP) kits for skeletal scintigraphy and imaging of areas of increased osteogenic activity. The diagnostic imaging agent is the technetium-labelled product, not unlabelled medronic acid alone.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/technetium-tc-99m-medronate · https://www.safetyandquality.gov.au/medicine-finder/radpharm-mdp · https://www.ncbi.nlm.nih.gov/mesh/68013669

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Medronic Acid Environmental Risk Assessment (ERA) (the Medronic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.